Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion
/in Glioblastoma, International Publications, Newcastle Disease VirusRelationship between Energy Dosage and Apoptotic Cell Death by Modulated Electro-Hyperthermia
/in Hyperthermia, International PublicationsDendritic cell vaccine as an alternative to opioid analgesia in patients with advanced cervical cancer.
/in Cervical Cancer, Dendritic Cells, International PublicationsDendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer
/in Colorectal Cancer, Dendritic Cells, International PublicationsAddition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusOptimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses
/in International Publications, Newcastle Disease VirusFeasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1
/in Dendritic Cells, Glioblastoma, International PublicationsHyperthermia and protein homeostasis: Cytoprotection and cell death
/in Hyperthermia, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer